2007
Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users
Mehta S, Lucas G, Astemborski J, Kirk G, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007, 19: 637-645. PMID: 17505924, DOI: 10.1080/09540120701235644.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyRisk of progressionVirologic responseTreatment interruptionImmunologic responseAntiretroviral therapyCommunity-based injection drug usersDrug usersMultiple Cox regression analysisRecent outpatient visitYears of HAARTCox regression analysisInjection drug useNew AIDS diagnosesSubsequent disease progressionEarly responseHAART initiationHAART initiatorsHIV careOutpatient visitsCox regressionPrognostic valueAIDS diagnosisPoor response
2006
Physical activity in a cohort of HIV-positive and HIV-negative injection drug users
Smit E, Crespo C, Semba R, Jaworowicz D, Vlahov D, Ricketts E, Ramirez-Marrero F, Tang A. Physical activity in a cohort of HIV-positive and HIV-negative injection drug users. AIDS Care 2006, 18: 1040-1045. PMID: 17012097, DOI: 10.1080/09540120600580926.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-positive participantsHIV-positive injection drug usersInjection drug useHIV-negativeVigorous activityPhysical activityDrug usersDrug usePaffenbarger Physical Activity QuestionnaireRecent injection drug usersHIV-negative injection drug usersIntravenous Experience cohortActive antiretroviral therapyCohort of HIVHIV-negative participantsPhysical Activity QuestionnairePhysical activity levelsAntiretroviral therapyHIV infectionViral loadHIV treatmentActivity QuestionnaireAnthropometric measurementsEnergy expenditure
2005
Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy
Rusch M, Farzadegan H, Tarwater P, Safaeian M, Vlahov D, Strathdee S. Sexual Risk Behavior Among Injection Drug Users Before Widespread Availability of Highly Active Antiretroviral Therapy. AIDS And Behavior 2005, 9: 289-299. PMID: 16133905, DOI: 10.1007/s10461-005-9003-4.Peer-Reviewed Original ResearchConceptsInjection drug usersCondom useAntiretroviral therapyHIV testingDrug usersEligible injection drug usersRisk behaviorsActive antiretroviral therapyInconsistent condom useSexual risk behaviorsIDU cohortHIV transmissionRetrospective analysisLower riskStudy exposureSexual riskLong-term studiesTherapySignificant changesCounselingRiskExposureLogistic modelWidespread availabilityCohort
2004
Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users
Tun W, Gange S, Vlahov D, Strathdee S, Celentano D. Increase in Sexual Risk Behavior Associated with Immunologic Response to Highly Active Antiretroviral Therapy among HIV-Infected Injection Drug Users. Clinical Infectious Diseases 2004, 38: 1167-1174. PMID: 15095224, DOI: 10.1086/383033.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyHAART initiationCell countAntiretroviral therapyDrug usersSexual intercourseRisk reduction counselingHuman immunodeficiency virusLarge cohort studyDrug injection behaviorInjection of drugsUnprotected sexual intercourseSemiannual visitsReduction counselingCohort studyHIV infectionHIV serostatusImmunodeficiency virusImmunologic responseNeedle sharingBlood samplesSurvival analysisRisk behaviorsCD4
2002
Use of HIV Protease Inhibitors Is Associated with Left Ventricular Morphologic Changes and Diastolic Dysfunction
Meng Q, Lima J, Lai H, Vlahov D, Celentano D, Strathdee S, Nelson K, Tong W, Lai S. Use of HIV Protease Inhibitors Is Associated with Left Ventricular Morphologic Changes and Diastolic Dysfunction. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 30: 306-310. DOI: 10.1097/01.qai.0000017995.56638.f8.Peer-Reviewed Original ResearchPosterior wall thicknessHIV infectionHigher interventricular septum thicknessHIV protease inhibitor therapyLeft ventricular systolic functionLV posterior wall thicknessEarly peak velocityLate peak velocitiesNon-PI groupVentricular systolic functionCardiac valve regurgitationProtease inhibitor therapyInterventricular septum thicknessLog-transformed durationPeak velocityHIV protease inhibitorsAntiretroviral therapyDiastolic dysfunctionPI therapyVascular complicationsAtrial dimensionSystolic functionInhibitor therapyLV hypertrophyValve regurgitationHighly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users
Bouhnik A, Moatti J, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. Journal Of Epidemiology & Community Health 2002, 56: 349. PMID: 11964431, PMCID: PMC1732133, DOI: 10.1136/jech.56.5.349.Peer-Reviewed Original ResearchConceptsSexual risk behaviorsAntiretroviral treatmentDrug usersRisk behaviorsPrescription of HAARTActive antiretroviral therapyProportion of patientsActive antiretroviral treatmentUnprotected sexual intercourseFrench HIVAntiretroviral therapyClinical improvementCohort studyTreatment-NaiveHIV transmissionAIDS careHAARTHIV riskHigh-risk activitiesHospital departmentsSexual riskHIVSexual intercourseMultivariate modelLongitudinal analysis
2001
Cancer incidence in women with or at risk for HIV
Phelps R, Smith D, Heilig C, Gardner L, Carpenter C, Klein R, Jamieson D, Vlahov D, Schuman P, Holmberg S, Group S. Cancer incidence in women with or at risk for HIV. International Journal Of Cancer 2001, 94: 753-757. PMID: 11745473, DOI: 10.1002/ijc.1528.Peer-Reviewed Original ResearchConceptsInvasive cervical cancerLung cancerHigh-risk human immunodeficiency virusRace-matched womenCurrent antiretroviral therapyHistory of smokingMonths of diagnosisInjection drug useHuman immunodeficiency virusHIV Epidemiology Research StudyCare of womenRates of cancerCancer incidence dataInterval diagnosisUninfected womenAntiretroviral therapyHIV infectionStudy closureCervical cancerImmunodeficiency virusYoung smokersHodgkin's lymphomaMedical recordsCancer incidenceKaposi's sarcomaSexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users
Vlahov D, Safaien M, Lai S, Strathdee S, Johnson L, Sterling T, Celentano D. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001, 15: 2311-2316. PMID: 11698705, DOI: 10.1097/00002030-200111230-00013.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seropositive injection drug usersActive antiretroviral therapyUntreated groupHigh-risk behaviorsAntiretroviral therapyConsecutive visitsDrug usersRisk behaviorsInitiation of HAARTCD4 cell countOngoing prospective studySemi-annual interviewsLinear growth curve analysesHAART useMedian ageMedication useProspective studyNeedle sharingHAARTCell countUnprotected sexRisk-related behaviorsCurve analysisStudy periodInfluence of Injection Drug Use Behavior on Reported Antiretroviral Therapy Use Among Women in the HIV Epidemiology Research Study: On-Site Versus Referral Care.
Rompalo A, Shah N, Mayer K, Schuman P, Klein R, Smith D, Vlahov D. Influence of Injection Drug Use Behavior on Reported Antiretroviral Therapy Use Among Women in the HIV Epidemiology Research Study: On-Site Versus Referral Care. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 28. PMID: 11579274, DOI: 10.1097/00042560-200109010-00005.Peer-Reviewed Original ResearchConceptsInjection drug useInjection drug usersAntiretroviral therapy useAntiretroviral therapyART useDrug usersDrug useHIV careTherapy useSelf-reported injection drug useMedical careCD4 cell count categorySelf-reported ART useActive injection drug usersSexual contactFemale injection drug usersInjection drug use behaviorsPneumocystis carinii prophylaxisActive antiretroviral therapyProspective cohort studyHIV Epidemiology Research StudyHealth care providersCross-sectional analysisDrug use behaviorsReferral careInfluence of Injection Drug Use Behavior on Reported Antiretroviral Therapy Use Among Women in the HIV Epidemiology Research Study: On-Site Versus Referral Care
Rompalo A, Shah N, Mayer K, Schuman P, Klein R, Smith D, Vlahov D. Influence of Injection Drug Use Behavior on Reported Antiretroviral Therapy Use Among Women in the HIV Epidemiology Research Study: On-Site Versus Referral Care. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 28-34. DOI: 10.1097/00126334-200109010-00005.Peer-Reviewed Original ResearchInjection drug useInjection drug usersAntiretroviral therapy useAntiretroviral therapyART useDrug usersDrug useHIV careTherapy useSelf-reported injection drug useMedical careCD4 cell count categorySelf-reported ART useActive injection drug usersSexual contactFemale injection drug usersInjection drug use behaviorsPneumocystis carinii prophylaxisActive antiretroviral therapyProspective cohort studyHIV Epidemiology Research StudyHealth care providersCross-sectional analysisDrug use behaviorsReferral careTime to initiating highly active antiretroviral therapy among HIV-infected injection drug users
Celentano D, Galai N, Sethi A, Shah N, Strathdee S, Vlahov D, Gallant J. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001, 15: 1707-1715. PMID: 11546947, DOI: 10.1097/00002030-200109070-00015.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyAntiretroviral therapyDrug usersCell countLow health care accessNon-HAART regimensAntiretroviral therapy useDual combination therapyProportional hazards regressionMain outcome measuresMore treatment optionsHealth care accessNon-drug usersHAART regimenLow CD4HAART useHIV careCohort studyStudy clinicTherapy useSelf-reported initiationHazards regressionMethadone treatmentTreatment eligibilityHighly Active Antiretroviral Therapy Associated with Improved Anemia Among HIV-Infected Women
Semba R, Shah N, Klein R, Mayer K, Schuman P, Gardner L, Vlahov D. Highly Active Antiretroviral Therapy Associated with Improved Anemia Among HIV-Infected Women. AIDS Patient Care And STDs 2001, 15: 473-480. PMID: 11587633, DOI: 10.1089/108729101753145466.Peer-Reviewed Original ResearchConceptsPrevalence of anemiaAntiretroviral therapyHuman immunodeficiency virus (HIV) infectionActive antiretroviral therapyCombination antiretroviral therapyImmunodeficiency virus infectionHIV-positive womenYears of treatmentIncrease of hemoglobinImproved anemiaMulticenter cohortVirus infectionHAARTAnemiaHIVWomenTherapyLinear regression modelsPrevalenceTreatmentBaselineHemoglobinRegression modelsSignificant changesMonotherapyImprovement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. PMID: 11317071, DOI: 10.1097/00126334-200104010-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBaltimoreBody Mass IndexCD4 Lymphocyte CountChronic DiseaseFemaleHemoglobinsHIV InfectionsHIV-1HumansLongitudinal StudiesMaleMultivariate AnalysisPrevalenceSex FactorsSubstance Abuse, IntravenousViral LoadConceptsInjection drug usersPlasma HIV loadActive antiretroviral therapyAntiretroviral therapyHIV loadOpportunistic infectionsCopies/Mean decreaseDrug usersHIV-positive injection drug usersPotent antiretroviral therapyImprovement of anemiaBody mass indexIncrease of hemoglobinAntiretroviral medicationsHIV infectionMass indexControl subjectsOverall prevalenceChronic diseasesAnemiaNutritional statusMean increaseMultivariate analysisHAARTImprovement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy
Semba R, Shah N, Vlahov D. Improvement of Anemia Among HIV-Infected Injection Drug Users Receiving Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 26: 315-319. DOI: 10.1097/00042560-200104010-00003.Peer-Reviewed Original ResearchInitial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men
Sterling T, Vlahov D, Astemborski J, Hoover D, Margolick J, Quinn T. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal Of Medicine 2001, 344: 720-725. PMID: 11236775, DOI: 10.1056/nejm200103083441003.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDisease-Free SurvivalEligibility DeterminationFemaleHIV AntibodiesHIV InfectionsHIV-1HumansLongitudinal StudiesMalePractice Guidelines as TopicRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRiskRNA, ViralSex FactorsViral LoadConceptsInitial viral loadMedian initial viral loadHIV-1 RNAViral loadLymphocyte countHuman immunodeficiency virus type 1 (HIV-1) infectionPlasma HIV-1 RNA levelsHIV-1 RNA levelsHIV-1 RNA copiesFemale injection drug usersVirus type 1 infectionHIV-1 seroconversionMedian initial CD4Risk of progressionHIV-1 infectionType 1 infectionInjection drug usersLikelihood of progressionRate of progressionAntiretroviral therapyInitial CD4Hazard ratioAntiretroviral treatmentTreatment guidelinesImmunodeficiency syndrome
2000
Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART
Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y, Group T. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug And Alcohol Dependence 2000, 60: 51-54. PMID: 10821989, DOI: 10.1016/s0376-8716(00)80007-1.Peer-Reviewed Original ResearchConceptsEfficacy of HAARTDrug usersBuprenorphine substitution treatmentViral load trendsActive antiretroviral therapyFrench cohort studyHIV viral loadUse of buprenorphineInjection drug usersVirologic responseAntiretroviral therapyCohort studyBuprenorphine treatmentTreatment initiationViral loadMaintenance treatmentPotential confoundersHAARTSubstitution treatmentBuprenorphineHIVIndividual treatmentPatientsTreatmentLinear regression modelsCervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women
Ahdieh L, Munoz A, Vlahov D, Trimble C, Timpson L, Shah K. Cervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women. American Journal Of Epidemiology 2000, 151: 1148-1157. PMID: 10905527, DOI: 10.1093/oxfordjournals.aje.a010165.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHIV SeronegativityHIV SeropositivityHumansImmunosuppression TherapyIncidenceLongitudinal StudiesPapillomaviridaePapillomavirus InfectionsRisk AssessmentSurvival AnalysisTumor Virus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsConceptsCervical intraepithelial neoplasiaHuman papillomavirus infectionHPV positivityHPV clearancePapillomavirus infectionHIV infectionBiopsy-confirmed cervical intraepithelial neoplasiaAssociation of HIVPotent antiretroviral therapyCervicovaginal lavage specimensHuman immunodeficiency virusCells/Reversal of immunosuppressionPolymerase chain reaction-based assaySeronegative womenAntiretroviral therapyHIV- womenHPV resultsHIV- participantsHPV DNACervical neoplasiaHIV serostatusIntraepithelial neoplasiaImmunodeficiency virusRelated immunosuppressionImproved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00126334-200004010-00005.Peer-Reviewed Original ResearchHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug useImproved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy.
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-6. PMID: 10836754, DOI: 10.1097/00126334-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsSerum alpha-tocopherol levelsAlpha-tocopherolPotent antiretroviral therapyAlpha-tocopherol levelsExcess oxidative stressOxidative stress levelsAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceDrug useHIVImproved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00042560-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug use